External
Quality Assurance (EQA) Program for
Neonatal
G6PD Screening Test
G6PD
EQA MIS System [login]
FAQ : [website
security certificate Problem]
Introduction¡G
¡@¡@Glucose-6-phosphate
dehydrogenase (G6PD; EC1.1.1.49) deficiency
is the most common enzymopathic disease in Southeast Asia and other tropical
areas worldwide. This X-linked genetic disorder (MIM 305900) has been found
to be an important cause of neonatal jaundice and acute haemolytic anemia in
the southern Chinese population in Taiwan. In order to reduce the complications
of G6PD deficiency, such as kernicterus, permanent neurological damage and death,
nationwide neonatal screening for G6PD deficiency was started on 1 July 1987
after a pilot project conducted between November 1984 and June 1987 had demonstrated
the practicality and the efficiency of neonatal screening of G6PD deficiency
in Taiwan. The effective collection rate has reached more than 99% of
all newborns in Taiwan since 1996 and the overall incidence rate of G6PD deficiency
was found to be about 2%. To
assess the reliability and to improve the quality of the screening tests performed
by each neonatal screening center, an external
quality assurance (EQA) program for determination for blood G6PD activity
was developed since 1999.
Periodically, 10 QC specimens were randomly picked for each survey and
distributed to each neonatal screening laboratory by speed post delivery.
Reports were requested to be returned by facsimile (and internet submission
since 2005) within 3 days for screening centers in Taiwan and 9 days for
overseas screening centers. For each QA survey, the G6PD activity of the
QC dried blood spots was determined by quantitative assay to set
the reference values before the QC specimens were send out. The results
reported by the screening centers were evaluated against the consensus result
and compared with the quantitative reference values determined by our
laboratory. The summary report for each survey was published on website
within two weeks after the survey started.
Participating Laboratories
Austria |
[ARCHIMED Life Science GmbH, Vienna] |
Belgium |
[Zentech] |
China (Mainland)
|
[First Affiliated Hospital of Xinjiang Medical University] [Foshan Neonatal
Screening Center] [Fujian
Neonatal Screening Center, Fuzhou] [Guangzhou
Neonatal Center] [Hunan Huaihua Maternal and Child Health Hospital] [Hunan
Neonatal Screening Center][Meizhou
Woman and Child Hospital Newborn Screening Center, Meizhou]
[Nanning Maternal and Child Health Hospital
of Guangxi Zhuang Autonomous Region, Nanning]
[Medical Genetics Center, Jiangmen Maternity and Child Health Care Hospital] [Qingdao Women and Children's Hospital] [Shanghai
Children's Hospital] [Shanghai Neonatal
Screening Center-Shanghai] [Shenzhen
Neonatal Screening Center] [Xiamen's
Maternal & Child Health Care Hospital]
[Yang Jiang City of Guang Dong Maternal
and Children's Hospital, Yangjiang] [Yueyang Maternal and Child Health Care Hospital] [Zhanjiang
Neonatal Screening Center] [Zhongshan
Neonatal Screening Center]
|
Finland
|
[Labsystems Diagnostics Ltd., Vantaa] |
Germany
|
[Screening-Labor
Hannover][Synlab
Weiden, Weiden] |
Greece
|
[BIOIATRIKI Group of Health, Athens]
[N.DIMOPOULOS SA- RD Diagnostics, Athens] |
India
|
[Dr
Lal PathLabs, New Delhi] [Tulip Diagnostics Pvt. Ltd] [Navigene Genetic Science Pvt. Ltd.] [Sir
Ganga Ram Hospital, New Delhi] [General Diagnostics International Private Limited, Navi Mumbai][Revvity Health Sciences Private Limited ( Chennai )] [Revvity Health Sciences Private Limited (Hyderabad)] |
Mexico
|
[Ensayos y Tamizajes de Mexico, S.A. de C.V., Mexico City] [Hospital General De Mexico Dr. Eduardo Liceaga, Mexico City] [Instituto de Ciencias Medicas para la Mujer S.A. de C.V. Laboratorio ciemta] [Instituto
Nacional de Perinatologia, Del. Miguel Hidalgo, Mexico City] [Tamiz Ampliado de Yucatan] [Tamizaje Plus S.A. de C.V., Merida] |
Philippines
|
[National
Institutes of Health, Manila]
[Newborn Screening Center-Central
Luzon, Angeles City] [Newborn
Screening Center-Central Visayas, Mandaue City] [Newborn
Screening Center-Mindanao, Davao City] [Newborn
Screening Center-Northern Luzon, Batac City] [Newborn
Screening Center-Southern Luzon, Tanauan City]
[Newborn Screening Center-Visayas, Iloilo City] |
Taiwan
|
[CFOH,
Taipei] [NTU
Hospital, Taipei] [TIP,
Taipei] |
Thailand
|
[Lerdsin General Hospital, Bangkok] [Queen
Sirikit National Institute of Child Health, Bangkok] |
Turkey
|
[Tanyalcin
Tip Laboratory, Izmir] |
Vietnam
|
[Genetic - Laboratory Department, Can Tho Gynecology and Obstetrics Hospital, Can Tho City] [Hanoi Hospital of Obstetrics and Gynecology - Prenatal Diagnosis and Newborn Screening Center, Hanoi] [Hue University of Medicine and Pharmacy, Hue] [Isolabo Medical Laboratory, Ho Chi Minh City] [Tu
Du Hospital, Ho Chi Minh City] |
Summary Report of EQA Survey for Neonatal G6PD Screening Test :
January 2024~
¡@¡@¡@¡@ 1. Survey
No : NS2024-01
¡@¡@¡@¡@ 2. Survey
No : NS2024-02
July 1998~December
2023
Preventive Medicine Foundation
Address : P.O. Box 624 Taipei Xinwei, Taiwan, 10699
TEL : +886-2-2703-6080 ; Fax : +886-2-2703-6070
E-mail :
updated : 23 Jul, 2024
[Home]